{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:10:45Z","timestamp":1792782645736,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna","id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bone scintigraphy using [99mTc]Tc-DPD or [99mTc]Tc-HMDP is a non-invasive cornerstone for diagnosing transthyretin cardiac amyloidosis (ATTR-CA). However, their interchangeability and the clinical relevance of systemic extracardiac uptake (ExtCU) remain poorly defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To systematically compare the diagnostic performance and whole-body biodistribution profiles of [99mTc]Tc-DPD and [99mTc]Tc-HMDP in patients with suspected cardiac amyloidosis (CA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated a multicenter cohort of patients investigated for suspected CA who underwent late planar whole-body scintigraphy and targeted SPECT\/CT with either radiotracer as part of their diagnostic workup. Inclusion required a final, confirmed diagnosis of ATTRwt, ATTRv, or AL amyloidosis. Myocardial visual Perugini score (VISUAL_PS) and systemic ExtCU (pulmonary, appendicular muscular, visceral, and miscellaneous) were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 224 patients (DPD:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009109, comprising 70 ATTRwt, 20 ATTRv, 19 AL; HMDP:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009115, comprising 90 ATTRwt, 13 ATTRv, 12 AL). In ATTRwt, the DPD cohort presented predominantly with Perugini Grade 2 (76%), whereas the HMDP cohort skewed toward Grade 3 (72%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). DPD was significantly associated with appendicular muscular uptake (ATTRwt: 84% vs. 38%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), creating a competitive \u201csoft-tissue sink effect\u201d. Conversely, HMDP demonstrated a unique predilection for pulmonary retention (ATTRwt: 68% vs. 46%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008; ATTRv: 61% vs. 10%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). Visceral uptake was rare in ATTR but was a robust negative predictor strongly favoring AL amyloidosis (OR 0.016,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>[99mTc]Tc-DPD and [99mTc]Tc-HMDP possess distinct biodistribution profiles precluding direct interchangeability. HMDP maximizes myocardial contrast, whereas DPD provides a superior representation of the systemic musculoskeletal amyloid burden. Nuclear medicine physicians must adopt tracer-specific interpretive approaches to optimize non-invasive phenotyping.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08153-1","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:02:06Z","timestamp":1792738926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of extracardiac radiotracer biodistribution in the evaluation of cardiac amyloidosis: a retrospective multicenter study on [99mTc]Tc-DPD and [99mTc]Tc-HMDP"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3973-4409","authenticated-orcid":false,"given":"Andrea","family":"Di Giorgio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Battisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Bonazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Elisa","family":"Prisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Starace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Longhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Bonfiglioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"8153_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/978-3-319-67144","volume":"1031","author":"AM Moliner","year":"2017","unstructured":"Moliner AM, Waligora J. The European Union Policy in the Field of Rare Diseases. Adv Exp Med Biol. 2017;1031:561\u201387. https:\/\/doi.org\/10.1007\/978-3-319-67144-. 4_30 PubMed PMID: 29214592.","journal-title":"Adv Exp Med Biol"},{"issue":"18","key":"8153_CR2","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/cvr\/cvac","volume":"118","author":"A Porcari","year":"2023","unstructured":"Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023;118(18):3517\u201335. https:\/\/doi.org\/10.1093\/cvr\/cvac. 119 PubMed PMID: 35929637; PubMed Central PMCID: PMC9897687.","journal-title":"Cardiovasc Res"},{"issue":"12","key":"8153_CR3","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","volume":"68","author":"RH Falk","year":"2016","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016;68(12):1323\u201341. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.053 . PubMed PMID: 27634125.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"8153_CR4","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3390\/jcm15041499","volume":"15","author":"MH Harbi","year":"2026","unstructured":"Harbi MH, Alzahrani YA. Emerging Pharmacological Strategies for Cardiac Amyloidosis: A Qualitative Analysis of Interventional Clinical Trials Registered on ClinicalTrials.Gov. J Clin Med. 2026;15(4):1499. https:\/\/doi.org\/10.3390\/jcm15041499 . PubMed PMID: 41753187.","journal-title":"J Clin Med"},{"issue":"11","key":"8153_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316. 10. 1056\/NEJMoa1805689 PubMed PMID: 30145929.","journal-title":"N Engl J Med"},{"issue":"22","key":"8153_CR6","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003 . PubMed PMID: 31171094; PubMed Central PMCID: PMC6724183.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"8153_CR7","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072 . PubMed PMID: 33825853; PubMed Central PMCID: PMC8060056.","journal-title":"Eur Heart J"},{"issue":"1","key":"8153_CR8","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):e7\u201322. 10. 1161\/CIR.0000000000000792 PubMed PMID: 32476490.","journal-title":"Circulation"},{"issue":"11","key":"8153_CR9","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","volume":"15","author":"DF Hutt","year":"2014","unstructured":"Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15(11):1289\u201398. https:\/\/doi.org\/10.1093\/ehjci\/jeu107 . PubMed PMID: 24939945.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"11","key":"8153_CR10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamacardio.2024.2555","volume":"9","author":"A Porcari","year":"2024","unstructured":"Porcari A, Masi A, Martinez-Naharro A, Razvi Y, Patel R, Ioannou A, et al. Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis. JAMA Cardiol. 2024;9(11):982\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2024.2555 . PubMed PMID: 39167388; PubMed Central PMCID: PMC11339700.","journal-title":"JAMA Cardiol"},{"issue":"16","key":"8153_CR11","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072 . PubMed PMID: 33825853; PubMed Central PMCID: PMC8060056.","journal-title":"Eur Heart J"},{"issue":"24","key":"8153_CR12","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404\u201312. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612 . PubMed PMID: 27143678.","journal-title":"Circulation"},{"issue":"11","key":"8153_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2019.08","volume":"25","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, ASNC\/AHA\/ASE\/EANM\/HFSA, et al. \/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. J Card Fail. 2019;25(11):e1\u201339. https:\/\/doi.org\/10.1016\/j.cardfail.2019.08. .001 PubMed PMID: 31473268.","journal-title":"J Card Fail"},{"issue":"6","key":"8153_CR14","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.073 . PubMed PMID: 16168294.","journal-title":"J Am Coll Cardiol"},{"key":"8153_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ijcard.2017.10.027","volume":"254","author":"F Cappelli","year":"2018","unstructured":"Cappelli F, Gallini C, Costanzo EN, Tutino F, Ciaccio A, Vaggelli L, et al. Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon. Int J Cardiol. 2018;254:346\u201350. https:\/\/doi.org\/10.1016\/j.ijcard.2017.10.027 . PubMed PMID: 29407121.","journal-title":"Int J Cardiol"},{"issue":"23","key":"8153_CR16","doi-asserted-by":"publisher","first-page":"7210","DOI":"10.3390\/jcm13237210","volume":"13","author":"F Triposkiadis","year":"2024","unstructured":"Triposkiadis F, Briasoulis A, Xanthopoulos A. Amyloids and the Heart: An Update. J Clin Med. 2024;13(23):7210. doi:10.3390\/jcm13237210 PubMed PMID: 39685666; PubMed Central PMCID: PMC11642274.","journal-title":"J Clin Med"},{"issue":"6","key":"8153_CR17","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, ASNC\/AHA\/ASE\/EANM\/HFSA, et al. \/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2\u2014evidence base and standardized methods of imaging. J Nuclear Cardiol. 2019;26(6):2065\u2013123. https:\/\/doi.org\/10.1007\/s12350-019-01760-6.","journal-title":"J Nuclear Cardiol"},{"issue":"8\u201310","key":"8153_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/BF00998166","volume":"16","author":"S Janssen","year":"1990","unstructured":"Janssen S, Piers DA, van Rijswijk MH, Meijer S, Mandema E. Soft-tissue uptake of 99mTc-diphosphonate and 99mTc-pyrophosphate in amyloidosis. Eur J Nucl Med. 1990;16(8\u201310):663\u201370. 10. 1007\/BF00998166 PubMed PMID: 2166666.","journal-title":"Eur J Nucl Med"},{"issue":"11","key":"8153_CR19","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","volume":"15","author":"DF Hutt","year":"2014","unstructured":"Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15(11):1289\u201398. https:\/\/doi.org\/10.1093\/ehjci\/jeu107 . PubMed PMID: 24939945.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"8153_CR20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ijcard.2017.10.027","volume":"254","author":"F Cappelli","year":"2018","unstructured":"Cappelli F, Gallini C, Costanzo EN, Tutino F, Ciaccio A, Vaggelli L, et al. Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon. Int J Cardiol. 2018;254:346\u201350. https:\/\/doi.org\/10.1016\/j.ijcard.2017.10.027 . PubMed PMID: 29407121.","journal-title":"Int J Cardiol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08153-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08153-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08153-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:02:07Z","timestamp":1792738927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08153-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":20,"alternative-id":["8153"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08153-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"27 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author Andrea Di Giorgio, Giacomo Battisti, Norma Bonazzi, Sonia Elisa Prisco, Maria Starace, Simone Longhi, Valentina Berti e Francesco Cappelli declare they have no financial interests. Rachele Bonfiglioli received consulting fees, travel fees, or honoraria from Pfizer. Stefano Fanti reports, outside the submitted work, personal honoraria from Novartis and personal fees from AAA, Amgen, Astellas, Bayer, Debio, GE Healthcare, Immedica, Janssen, Sofie, and Telix.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}